Connect Biopharma Holdings Limited (Nasdaq: CNTB) shares plunged more than 32% on September 15 after its Phase 2 Seabreeze STAT Asthma study failed to achieve statistical significance on the prespecified primary endpoint, even though rademikibart produced a large numerical reduction in treatment failures and a statistically significant improvement in lung function. The stock closed at $1.17 after trading as low as roughly $1.06, with volume surging to about 11.6 million shares as investors reassessed the company’s proposed acute-exacerbation strategy.
The clinical result is more nuanced than the share-price reaction suggests. A single 600 mg subcutaneous dose of rademikibart reduced the 28-day treatment failure rate by approximately 66% compared with placebo, but the p-value was 0.153 and therefore failed the trial’s predefined statistical test. Connect Biopharma attributed the miss primarily to a much lower overall treatment-failure rate than the study had anticipated when its statistical assumptions were developed.
The key secondary endpoint told a more favorable story. Post-bronchodilator forced expiratory volume in one second increased by 250 mL from baseline at Day 7 in patients receiving rademikibart versus 120 mL with placebo, producing a placebo-adjusted 130 mL advantage and a p-value of 0.023.
That leaves Connect Biopharma with evidence of pharmacological activity and a possible Phase 3 path, but not the unequivocally positive Phase 2 result investors had hoped to see.
Why did a 66% reduction in treatment failure still count as a failed primary endpoint?
Clinical trials are designed around both the size of an observed treatment difference and the statistical confidence surrounding that difference. A large relative reduction can therefore fail a predefined endpoint when the number of events is too small to exclude the possibility that the apparent difference arose partly through chance.
Seabreeze STAT Asthma enrolled 160 adults and adolescents with asthma and type 2 inflammation who were experiencing an acute exacerbation. Seventy-nine participants received rademikibart and 81 received placebo, with both groups also receiving standard treatment for the exacerbation.
Treatment failure was broadly defined to capture deterioration during the first 28 days. Events included death, hospitalization or rehospitalization for asthma, emergency-department or unscheduled medical visits for worsening symptoms, or the need to intensify pharmacological treatment.
The observed event rate was approximately 2.5% in the rademikibart group and 7.4% in the placebo group. That works out to a relative reduction of about two-thirds, which is clinically interesting but generated too few total events for the comparison to reach conventional statistical significance.
This is an important distinction for PDN and investor coverage. Saying that rademikibart reduced treatment failure by 66% is factually correct as a numerical trial result, but saying that the study proved a 66% reduction would overstate what the statistics support.
The primary endpoint missed. The signal can guide the next trial, but it cannot be treated as a confirmed efficacy finding.
Why was the placebo event rate so important to the outcome?
Event-driven endpoints depend heavily on assumptions made before a trial begins. Investigators estimate how often the relevant event will occur in the control population, then use that assumption to determine how many participants are needed to detect a clinically meaningful treatment difference with adequate statistical power.
If the placebo or standard-care event rate turns out substantially lower than expected, fewer events accumulate and the trial loses statistical power. That can happen even when the treatment arm performs numerically better.
The issue is particularly relevant in acute asthma because modern emergency treatment can be highly effective. Participants received contemporary standard of care, including therapies intended to stabilize airflow obstruction rapidly after an exacerbation.
If relatively few placebo-treated patients subsequently fail treatment, the experimental medicine has less statistical room to demonstrate further improvement unless the study enrolls substantially more people.
Connect Biopharma now has real event-rate data that can inform Phase 3 sample-size calculations. This is one reason management describes the study as providing a roadmap despite the primary-endpoint failure.
Regulators will decide whether they share that interpretation. FDA discussions after the upcoming COPD readout should clarify whether a larger treatment-failure study remains appropriate or whether lung function can carry greater weight in a registrational program.
Why could the 130 mL FEV1 difference provide a viable Phase 3 path?
Forced expiratory volume in one second is an objective measure of how much air a person can forcefully exhale during the first second of a pulmonary-function test. It is widely used to quantify airflow limitation in asthma and chronic obstructive pulmonary disease.
At Day 7, rademikibart-treated patients improved by 250 mL from baseline compared with 120 mL among placebo recipients. The difference of 130 mL was statistically significant at p=0.023.
That result is notable because rademikibart was administered on top of standard acute-exacerbation treatment rather than instead of it. The antibody therefore produced additional lung-function improvement in patients already receiving therapies intended to restore airway function.
Connect Biopharma has said the Day 7 FEV1 measure is its proposed primary endpoint for a future Phase 3 program. Such a change would make the next study test the clinical variable that actually achieved statistical significance in Phase 2 instead of repeating a primary endpoint undermined by unexpectedly low event rates.
FDA agreement will be critical. A statistically convenient endpoint is not automatically an acceptable registrational endpoint, and regulators will consider whether the magnitude of FEV1 improvement is clinically meaningful and whether it connects sufficiently to the proposed acute-exacerbation indication.
The company will also need to demonstrate that any lung-function advantage is reproducible in a larger and appropriately powered trial.
How does rademikibart work during an acute asthma exacerbation?
Rademikibart is a monoclonal antibody targeting interleukin-4 receptor alpha, a receptor component shared by signaling pathways for IL-4 and IL-13. These cytokines are central drivers of type 2 inflammation, a common biological pattern in many patients with asthma.
Blocking IL-4R alpha is already clinically validated in chronic inflammatory disease. The novel part of Connect Biopharma’s strategy is not the general pathway but the timing of treatment.
Biologic medicines for asthma have traditionally been positioned as maintenance therapies intended to reduce future exacerbations in patients with severe or uncontrolled disease. Connect is investigating whether rapid blockade of type 2 inflammation immediately after an exacerbation can improve recovery and reduce the chance that a patient deteriorates again during the vulnerable period after emergency treatment.
Seabreeze STAT specifically enrolled participants with evidence of type 2 inflammation, including elevated eosinophils. That biomarker selection increases the biological rationale because IL-4 and IL-13 signaling is most relevant when the disease is driven by the inflammatory pathway the drug targets.
The single-dose design is another unusual feature. Connect is not asking patients in this study to begin indefinite maintenance biologic treatment. It is testing whether one intervention during an acute episode can change the short-term course of recovery.
Could an acute-exacerbation biologic create a new asthma treatment category?
That is the larger commercial thesis behind rademikibart. Emergency departments currently treat acute asthma primarily with bronchodilators, systemic corticosteroids, oxygen and other supportive measures according to disease severity.
These therapies can stabilize the immediate attack, but some patients remain at elevated risk of relapse, another emergency visit or another exacerbation shortly after discharge.
A biologic capable of producing rapid improvement and lowering treatment failure could theoretically be administered in the emergency department or urgent-care setting as an adjunct to standard treatment. That would differ substantially from the existing model in which biologics are usually initiated through specialist pathways for chronic severe asthma.
Connect estimates that approximately 1.6 million emergency-department visits occurred in 2025 among U.S. patients experiencing acute asthma exacerbations with high type 2 inflammatory characteristics. Company estimates are not equivalent to an independently validated addressable market, but they illustrate why management views the indication as commercially meaningful.
The hospital setting also creates challenges. A new biologic must demonstrate enough immediate clinical value to justify cost, formulary inclusion and operational changes in an environment focused on rapid patient stabilization and discharge.
Health-economic evidence could therefore become critical. Reducing repeat emergency visits or hospital admissions may be more commercially persuasive than a lung-function number alone.
Why does the upcoming COPD study matter even more after the CNTB selloff?
Connect Biopharma expects results later in September from its separate Seabreeze STAT COPD Phase 2 study. That trial uses a similar strategy, administering rademikibart during an acute exacerbation in patients with type 2 inflammatory biology.
The COPD readout now carries greater importance because it can help determine whether the asthma result reflects a reproducible pharmacological effect across acute respiratory disease or a study-specific outcome.
A positive COPD study could strengthen the argument that IL-4R alpha blockade has a rapid role during acute type 2 exacerbations. A disappointing result would leave investors with one Phase 2 program that missed its primary endpoint and less evidence supporting a broad acute-care platform.
Connect has also begun an open-label study evaluating intravenous rademikibart in patients presenting for urgent treatment of asthma or COPD exacerbations. That program is intended to bridge the existing 600 mg subcutaneous dose to a 300 mg intravenous push formulation.
An intravenous option makes operational sense if the ultimate market includes hospitals and emergency departments, where IV administration is routine and rapid drug delivery may be preferable.
The entire Seabreeze STAT program is therefore converging on one strategic question: can rademikibart become a biologic used during an acute respiratory crisis rather than primarily as chronic maintenance therapy?
How much financial flexibility does Connect Biopharma have after the stock decline?
Connect reported approximately $31.5 million in cash, cash equivalents and short-term investments at June 30, 2026, down from about $44.3 million at the end of 2025. The company recorded a first-half net loss of approximately $36.7 million as clinical spending increased around the Seabreeze program.
Management previously said available resources should fund operations for at least one year from its August financial update. That gives Connect time to receive the COPD data and engage with FDA, but it is not an unusually large cash cushion for a company potentially preparing a substantially larger Phase 3 respiratory program.
The September stock decline complicates future financing economics because issuing equity at a lower valuation can create greater dilution for existing shareholders.
Partnerships represent another possibility. Rademikibart has already generated substantial clinical experience across inflammatory diseases, and a clearly defined Phase 3 path could make the asset more attractive to larger respiratory or immunology companies.
The asthma miss therefore affects more than scientific perception. It can influence the cost of funding the next development stage.
Why did CNTB lose a third of its value if the secondary endpoint was positive?
Biotechnology markets tend to place disproportionate weight on prespecified primary endpoints because those endpoints determine whether a trial formally succeeds or fails.
The 66% numerical treatment-failure reduction created an attractive headline, but the p-value of 0.153 made the statistical interpretation unavoidable. Investors expecting a clean positive trial instead received a result requiring explanation and regulatory redesign.
The lung-function endpoint offers a plausible path forward, but that path has not yet been endorsed by FDA for a Phase 3 registration program. Investors therefore have to assign probability to future regulatory alignment rather than simply discounting an already successful pivotal strategy.
The share-price reaction was correspondingly severe. CNTB closed down more than 32%, traded at a new 52-week low and changed hands at several times normal daily volume.
That does not prove the market’s interpretation is scientifically correct. It demonstrates how strongly small-cap biotechnology valuations react when a primary endpoint misses, even when other data remain potentially useful.
What should CNTB investors watch next?
The first catalyst is the Seabreeze STAT COPD topline readout expected later in September. Lung-function improvement, treatment-failure rates and consistency with the asthma dataset will be particularly important.
The second is FDA feedback on Phase 3 design. Investors need to know whether the agency accepts Day 7 FEV1 as a viable primary endpoint, whether another treatment-failure assessment will be required and what size study would support registration.
Detailed asthma data beyond the topline release will also matter. Subgroup analyses according to eosinophil levels, baseline severity, prior biologic use and treatment setting could help identify populations in which the treatment effect is most consistent.
Connect Biopharma has not emerged from Seabreeze STAT with the result investors wanted. The study missed its primary endpoint, and that fact should remain central to any coverage.
It also did not emerge with a biologically inactive drug. Rademikibart produced statistically significant rapid lung-function improvement and a large but statistically uncertain treatment-failure reduction.
The next phase of the CNTB story is therefore unusually clear. Connect must prove that the favorable signal can be converted into a prospectively designed Phase 3 endpoint rather than explained only after a failed primary analysis.
